English
Regional settings| Spread | 0.12 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 4.76 |
| Open | 4.84 |
| 1-Year Change | -0.41% |
| Day's Range | 4.84 - 4.91 |
Champions Oncology, Inc. is engaged in creating transformative technology solutions to be utilized in oncology drug discovery and development. This technology includes the Company’s in-vivo, ex-vivo and biomarker platforms, oncology software solutions, and computational-based discovery platforms. The Company’s TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology. The Company’s software as a service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. The Company’s drug discovery and development business leverages the computational and experimental capabilities within its platforms. Their discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify novel therapeutic targets.
BRIEF: For the nine months ended 31 January 2022, Champions Oncology Inc revenues increased 19% to $36.2M. Net income decreased 14% to $892K. Revenues reflect Pharmacology services segment increase of 66% to $34.5M, Other segment increase from $101K to $1.7M. Net income was offset by research and development increase of 32% to $6.8M (expense), general and administratiojn increase of 32% to $5.9M (expense).
Common Stock $.001 Par, 01/11, 50M auth., 36,853,000 issd. less 1,236,000 shs. in Treas. @ $292K. Insiders & strategic holders own 64.79%. Public Offering 9/85, 40M Units (1 sh. com. + 3 warrants) @ $.01 by the Company. 02/07, Name changedfrom Champions Sports Inc.08/15, 1-for-12 Reverse stock split.
